AR033984A1 - Derivados de pirrolidina, procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de medicamentos - Google Patents

Derivados de pirrolidina, procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de medicamentos

Info

Publication number
AR033984A1
AR033984A1 ARP010103416A ARP010103416A AR033984A1 AR 033984 A1 AR033984 A1 AR 033984A1 AR P010103416 A ARP010103416 A AR P010103416A AR P010103416 A ARP010103416 A AR P010103416A AR 033984 A1 AR033984 A1 AR 033984A1
Authority
AR
Argentina
Prior art keywords
arylcarbonyl
alkyl
arylalkyl
aryl
arylcarbonylalkyl
Prior art date
Application number
ARP010103416A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR033984A1 publication Critical patent/AR033984A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)

Abstract

Derivados de pirrolidina, que comprenden un compuesto de fórmula general (1) en donde R1 es hidrógeno, alquilcarbonilo o arilcarbonilo; R2 es alquilo, alquilcicloalquilo, alquilcicloalquilalquilo, cicloalquilo, halógenoalquilo, carboxialquilo, aminoalquilo, dialquilaminoalquilo, alcoxialquilo, alcoxicarbonilalquilo, alquinilo, arilo, arilalquilo, arilalquil(alcoxicarbonil)alquilo, arilcarbonilalquilo, ariloxialquilo, arilalquenilo, aril(alcoxicarbonil)alquilo, heteroarilo, heteroarilalquilo, heterociclilo o heterociclilalquilo; A es -C(O)-R3, -CH(OH)-R4, ó -C(O)-NR5R6, en donde R3 y R4 son independientemente del grupo formado por alquilo, arilo, arilalquinilo, arilalquilo y arilalquenilo; R5 es hidrógeno, alquilo, cicloalquilo, cicloalquilalquilo, carboxialquilo, o arilalquilo; R6 es alquilo, alquilcarbonilalquilo, cianoalquilo, hidroxialquilo, hidroxialquil-(hidroxialquilo), alcoxicarbonilalquilo, arilcarbonilalquilo, arilaminocarbonilalquilo, aril(alquil)aminocarbonil-alquilo, aminocarbonillaquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, cicloalquilo, cicloalquilalquilo, o carboxialquilo, o R6 se selecciona del grupo consistente en las fórmulas (2), (3) y (4) o -NR5R6 en -C(O)NR5R6 para A representa un anillo saturado de 5 o 6 miembros, sustituido opcionalmente con carboxi, alquiloxicarbonilo, hidroxi, alcoxicarbonilalcoxi, fenilalquilo o fenilalcoxicarbonilo, R7 es hidrógeno, alquilo, alquenilo, alquiltioalquilo, arilo, heteroarilo, carboxialquilo, carboxi, alcoxicarbonilalquilo, arilalquilo, o heteroarilalquilo; o un compuesto de fórmula 5, R7a es hidrógeno o alquilo; R8 es -OR9 o -NR10R11, en donde R9 es hidrógeno, alquilo, arilalquilo; R10 es hidrógeno o alquilo; y R11 es alquilo, arilo, heteroarilo, arilalquilo, o el grupo -NR10R11 representa un anillo de 5 ó 6 miembros opcionalmente sustituido con carboxi, alquiloxicarbonilo, hidroxi, alcoxicarbonilalcoxi, fenialaquilo o fenilalcoxicarbonilo; R12 es alquilo, arilo, o arilalquilo; Y es -O-, -O-S(O2)-, -O-C(O)- o -O-(C)-NH; m es 0, 1 o 2; X es -SO2, -CO-, -C(O)O-, -SO2NH-, o -C(O)NR13- en donde R13 es hidrógeno, alquilo, arilo o carboxialquilo; y formas diméricas, y/o ésteres farmacéuticamente aceptables, y/o sales farmacéuticamente aceptables, y/o sales farmacéuticamente aceptables de los mismos. Los compuestos son útiles como inhibidores de metaloproteasas, por ej. zinc proteasas, en particular zinc hidrolasas, y son efectivos en el tratamiento de enfermedades asociadas con la vasoconstricción de incidencia creciente. Se describen también un proceso para su preparación, composiciones farmacéuticas y el uso de dichos derivados para la fabricación de medicamentos para la profilaxis y tratamiento de trastornos que están causados por la actividad de la enzima conversora de endotelina (ECE), especialmente isquemia de miocardio, insuficiencia cardíaca congestiva, arritmia, hipertensión, hipertensión pulmonar, asma, vasoespasmo cerebral, hemorragia subaracnoidal, pre-eclampsia, enfermedades del rinón, aterosclerosis, enfermedad de Bueger, artritis de Takayasu, complicaciones diabéticas, cáncer de pulmón, cáncer prostático, trastornos gastroinstestinales, shock endotóxico y septicemia, y para la curación de heridas y control de la menstruación, glaucoma, rechazo de injertos, enfermedades asociadas con indicaciones citostáticas, oftalmológicas y cerebroprotectoras, y protección de órganos.
ARP010103416A 2000-07-19 2001-07-17 Derivados de pirrolidina, procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de medicamentos AR033984A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00114947 2000-07-19

Publications (1)

Publication Number Publication Date
AR033984A1 true AR033984A1 (es) 2004-01-21

Family

ID=8169224

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103416A AR033984A1 (es) 2000-07-19 2001-07-17 Derivados de pirrolidina, procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de medicamentos

Country Status (16)

Country Link
US (1) US6541638B2 (es)
EP (1) EP1303485A1 (es)
JP (1) JP4068452B2 (es)
KR (1) KR100568841B1 (es)
CN (1) CN1620433A (es)
AR (1) AR033984A1 (es)
AU (1) AU2001270627A1 (es)
BR (1) BR0112580A (es)
CA (1) CA2414311C (es)
GT (1) GT200100145A (es)
MX (1) MXPA03000223A (es)
PA (1) PA8522501A1 (es)
PE (1) PE20020294A1 (es)
UY (1) UY26847A1 (es)
WO (1) WO2002006222A1 (es)
ZA (1) ZA200300167B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100406439C (zh) * 2000-07-19 2008-07-30 霍夫曼-拉罗奇有限公司 作为金属蛋白酶抑制剂的吡咯烷衍生物
RU2290403C2 (ru) 2000-12-28 2006-12-27 Дайити Фармасьютикал Ко., Лтд. Ингибиторы vla-4
DE60336986D1 (de) 2002-03-05 2011-06-16 Sumitomo Chemical Co Verfahren zur herstellung von biarylverbindungen
EP1613269B1 (en) 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
WO2004092164A1 (en) 2003-04-10 2004-10-28 Amgen, Inc. Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
EP1631542A1 (en) 2003-04-10 2006-03-08 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
ATE388708T1 (de) 2003-06-20 2008-03-15 Amgen Inc Piperazinderivate und anwendungsverfahren
CN1826336B (zh) 2003-07-24 2010-06-02 第一制药株式会社 环己烷羧酸类
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
RU2435585C2 (ru) * 2006-04-13 2011-12-10 Актелион Фармасьютиклз Лтд Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких
ES2350548B1 (es) * 2009-06-25 2011-09-29 Institut Univ. De Ciència I Tecnologia, S.A. N-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
EP2730571A1 (en) * 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
JP7163916B2 (ja) * 2017-07-05 2022-11-01 日産化学株式会社 ベンジル化合物
CN110078593A (zh) * 2018-11-15 2019-08-02 南通正达农化有限公司 一种苹果蠹蛾性信息素的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
AU644008B2 (en) * 1990-08-10 1993-12-02 Sumitomo Pharmaceuticals Company, Limited Beta-lactam compounds, and their production and use
JP3091297B2 (ja) * 1992-01-10 2000-09-25 住友製薬株式会社 ピロリジン誘導体およびその製造方法
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
IL128666A (en) * 1996-08-28 2005-09-25 Procter & Gamble Substituted cyclic amine metalloprotease inhibitors
EP0998457A4 (en) * 1997-07-10 2010-03-10 CRYSTALLINE FORMS OF INTERMEDIATES OF ANTIBIOTICASE CHAINS
BR9910098A (pt) * 1998-05-01 2000-12-26 Kyoto Pharma Ind Derivados de carbapenem, utilização dos mesmos e compostos intermediários dos mesmos

Also Published As

Publication number Publication date
AU2001270627A1 (en) 2002-01-30
BR0112580A (pt) 2003-06-17
GT200100145A (es) 2002-05-16
CA2414311C (en) 2008-01-08
EP1303485A1 (en) 2003-04-23
PE20020294A1 (es) 2002-04-17
JP4068452B2 (ja) 2008-03-26
US20020049243A1 (en) 2002-04-25
KR100568841B1 (ko) 2006-04-10
CN1620433A (zh) 2005-05-25
UY26847A1 (es) 2002-01-31
ZA200300167B (en) 2004-04-07
PA8522501A1 (es) 2002-09-17
US6541638B2 (en) 2003-04-01
JP2004504297A (ja) 2004-02-12
CA2414311A1 (en) 2002-01-24
MXPA03000223A (es) 2003-06-06
WO2002006222A1 (en) 2002-01-24
KR20030016416A (ko) 2003-02-26

Similar Documents

Publication Publication Date Title
AR033984A1 (es) Derivados de pirrolidina, procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de medicamentos
NO20073730L (no) Amidderivater
MY140729A (en) Amide derivatives
PT1678166E (pt) Inibidores de proteína-quinase
JP2017512789A (ja) ジヒドロピリミジン化合物及び医薬におけるその適用
WO2008076805B1 (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
NO20053748L (no) Pyrrolopyridazinderivater.
TW200635918A (en) Pharmaceutical compounds
NZ543897A (en) Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
TW200716541A (en) The preparation and use of compounds as protease inhibitors
NO943910L (no) Laktam-peptider med HLE-hemmende virkning
RS60503A (en) Substituted alkylamine derivatives and methods of use
HUT61732A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions comprising same as active ingredient
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
TNSN05188A1 (en) 4-aminopyrimidine-5-one
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
DK0647219T3 (da) Derivater i vitamin D-serien modificeret i 20-positionen, fremgangsmåde til fremstilling af sådanne derivater, mellemprodukter itl brug ved fremgangsmåde, farmaceutiske præparater indeholdende derivaterne samt deres anvendelse ved fremstilling af lægemidler
IL257240A (en) History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication
ATE357453T1 (de) Comt-inhibitoren
MX2007001267A (es) Derivados de naftiridinas 2,8-disustituidas.
NO943909L (no) Laktam-dipeptider som har HLE-inhiberende aktivitet

Legal Events

Date Code Title Description
FB Suspension of granting procedure